Additional Information for Vaccinia Immune Globulin
Vaccinia Immune Globulin (VIG) is a type of immunoglobulin that is used for the treatment of complications associated with smallpox vaccination. It is derived from the plasma of individuals who have been immunized with the vaccinia virus.
VIG is classified as a drug and biological product and falls under the supply class of Drugs And Biologicals. It is included in the supply group of Medical, Dental, And Veterinary Equipment And Supplies.
VIG is typically administered to individuals who experience severe adverse reactions to the smallpox vaccine, such as progressive vaccinia, eczema vaccinatum, or generalized vaccinia. These complications can occur in individuals with weakened immune systems or certain pre-existing conditions.
The use of VIG helps to neutralize the vaccinia virus and reduce the severity of the adverse reactions. It provides passive immunity by transferring antibodies from the plasma of immunized individuals to the recipient.
VIG is usually administered intravenously and requires a prescription from a healthcare professional. It is important to follow the recommended dosage and administration guidelines provided by the healthcare provider.
Please note that the information provided here is for informational purposes only, and it is always recommended to consult with a healthcare professional for specific medical advice or information about Vaccinia Immune Globulin.
Related Item Names for INC 34441 Vaccinia Immune Globulin
NATO Stock Numbers with Item Name 34441 Vaccinia Immune Globulin Page 1 of 1
- 02-1924
- RNCC: 5 | RNVC: 1 | DAC: 4
- 06-0591
- RNCC: 5 | RNVC: 1 | DAC: 4
- VACCINICIMMUNGLOBULINHUMIV50000U
- RNCC: 3 | RNVC: 2 | DAC: 3
- J06BB
- RNCC: 5 | RNVC: 9 | DAC: 9
- GLOBULIN,VACCINIA
- RNCC: 5 | RNVC: 9 | DAC: 4
- VIGIV/CNJ-016
- RNCC: 5 | RNVC: 2 | DAC: 3